Neuronetics To Present Clinical Data at The American Psychiatric Association 2021 Annual Meeting
April 29 2021 - 7:00AM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, announced today it will present
clinical data in virtual poster sessions as part of the American
Psychiatric Association’s Annual Meeting virtual programming.
The American Psychiatric Association is the leading professional
psychiatric organization in the U.S. and is hosting virtual events
this year May 1-3 in place of its traditional Annual Meeting,
giving attendees a chance to experience sessions remotely.
Neuronetics is a Gold sponsor of the event and will host two poster
presentations on the company’s latest research with NeuroStar
Advanced Therapy for Mental Health in patients with Major
Depressive Disorder (MDD).
On Monday, May 3, Neuronetics will present real-world clinical
data, addressing the following topics:
- Clinical Outcomes in a Large Registry of Patients With
Major Depressive Disorder Treated With Transcranial Magnetic
Stimulation (#P12-086, 3:30 p.m. EST)Data from over 5,000
patients in NeuroStar’s Outcomes Registry was recently published in
an issue of the Journal of Affective Disorders suggesting NeuroStar
Advanced Therapy as a first-line treatment for Major Depressive
Disorder. Data will be presented by Harold A Sackeim, PhD,
Professor of Clinical Psychology in Psychiatry and Radiology at the
College of Physicians and Surgeons, Columbia University.
- Response, Meaningful Improvement, and Remission in
Real-World Patients With Major Depressive Disorder and
Comorbidities Treated With TMS (#P12-022, 3:30 p.m.
EST)Positive treatment results were shown using
transcranial magnetic stimulation in Major Depressive Disorder
patients with various comorbidities such as Persistent Depressive
Disorder (PDD), Generalized Anxiety Disorder (GAD), Borderline
Personality Disorder (BPD), and Post-Traumatic Stress Disorder
(PTSD). Data will be presented by Simon Kung, MD, Associate
Professor of Psychiatry at Mayo Clinic Rochester.
Neuronetics will also host a virtual exhibit booth at the event,
offering attendees the opportunity to learn more about the
NeuroStar Advanced Therapy for Mental Health treatment for MDD and
its 5 STARS to Success Program for NeuroStar practices. Plan to
visit and connect with someone from Neuronetics at the booth
located within the “Virtual Exhibit Gallery” of the APA virtual
meeting portal.
With 3.5 million treatments delivered across over 900 practice
locations in the United States, Neuronetics continues to be a
depression treatment industry leader. For more information,
visit www.neurostar.com.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Its commercial
product, the NeuroStar® Advanced Therapy System, is a non-invasive
and non-systemic office-based treatment that uses transcranial
magnetic stimulation, or TMS, to create a pulsed, MRI-strength
magnetic field that induces electrical currents designed to
stimulate specific areas of the brain associated with mood. The
system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. Visit NeuroStar.com for safety information and indications
for use. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national
health insurance. Additional information can be found
at www.neuronetics.com.
Media Contact:Chelsey MankoVault
Communications610-455-2778cmanko@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Apr 2024 to May 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From May 2023 to May 2024